Last reviewed · How we verify

NCT06832878

Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty

Not yet recruiting Phase 4 Last updated 29 January 2026
What this trial tests

Phase 4 trial testing Oral Tranexamic Acid in Arthroplasty in 101 participants. Not yet recruiting.

Timeline
1 June 2026
Primary endpoint
1 June 2026
1 June 2026

Quick facts

Lead sponsorMayo Clinic
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment101
Start date1 June 2026
Primary completion1 June 2026
Estimated completion1 June 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Arthroplasty. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Oral Tranexamic Acid

Trials testing the same drug.

Other recruiting trials for Arthroplasty

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06832878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing